Does Neptune Bio produce influenza A vaccine?

At present, the production capacity of 1 million doses is expected to enter the market in the near future

In the future, Haiwang Intelon, a subsidiary company listed in Hong Kong, will cooperate with GSK (GlaxoSmithKline) to improve the production capacity of influenza pandemic vaccine by using GSK patented adjuvant;

Neptune Intelon predicts that the annual production capacity of the joint venture company will reach more than 1 million doses of influenza vaccine in the future, making it one of the largest production bases of influenza vaccine in Asia with high quality. Haiwang Intelon Company is raising 6 million yuan by issuing H shares to strengthen the production capacity of influenza A vaccine.

The market outlook will gain greater opportunities for speculation.